A frequent reason for discontinuation of therapy is dry mouth, which is reported by as many as 80% of patients receiving the immediate-release formulation of oxybutynin (widely considered the ...

A study comparing a new topical gel formulation of oxybutynin to placebo has confirmed its efficacy and tolerability for treating overactive bladder. New formulations of oxybutynin have been ...

Objective: To evaluate the cost-effectiveness of a new extended-release (XL) formulation of oxybutynin relative to tolterodine immediate release (IR), currently the most prescribed treatment for ...

Oxybutynin chloride 5mg, 10mg; ext-rel tabs. Oxybutynin relaxes bladder smooth muscle. Oxybutynin chloride exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action ...